← All trials
NCT04478292
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Mar 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Jul 20, 2020
- Last posted
- Jul 20, 2020
- Enrollment
- 330
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Fudan UniversityCollaborator
- Jiao Tong UniversityCollaborator
- University of CincinnatiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.